Melanoma research reaches a milestone
21 March 2017
Melanoma research has reached a milestone with the 10,000th patient giving their permission for their blood and tissue samples to be used in the world’s largest melanoma biospecimen bank.
Melanoma Institute Australia (MIA) has been collecting samples from melanoma patients since 1999 and now has an incredible resource that is powering melanoma research here and around the globe. Together with patient records, the samples add enormous value to the clinical stories of our patients and drive discovery and translational research that will, in turn, provide answers to the clinical questions plaguing our doctors.
“When a patient first presents to MIA, we don't have the crystal ball to predict what their journey is going to be like,” says Biospecimen Bank Manager, Valerie Jakrot (pictured). “We now know that melanoma is not just one disease, and so we must look at the molecular level to understand the differences between each type.”
Because of the large number of samples collected, MIA and collaborators from around the world have access to a wide variety of different types of melanoma, including some of the rarer forms, growing our understanding of the disease. In addition, a large number of samples are needed to test and confirm hypotheses in research, and so the Biospecimen Bank’s magnitude is invaluable.
By using the samples to identify which genes drive the disease, researchers will gain a better understanding to improve patient outcomes. This is the basis of personalised medicine.
“By finding out which genes are involved in causing a patient’s melanoma, we will be able to better predict the course of the disease and identify which treatment will be most effective for the patient,” says Valerie. “This knowledge will change the management of patients from the very beginning, ensuring the best possible outcome is reached.”
Biospecimen Bank samples have also been used in a number of key research projects, including the Australian Melanoma Genome Project, which is mapping the entire genome of 500 melanomas. Our samples have contributed significantly to The Cancer Genome Atlas (TCGA), a five year study of tumours from over 300 patients around the world. In addition, data has been made available to the International Cancer Genome Consortium (ICGC), which is seeking to understand the genetic causes of 50 different cancer types.
Contributions making a difference
As the largest collection of melanoma blood and tissue samples in the world, the Biospecimen Bank would not have been established without significant resources from MIA. Being a specialised treatment centre, MIA has access to a large number of patients who generously consent to being part of this endeavour. Without the support of our patients, and donors who see the long-term potential of this project, the Biospecimen Bank simply wouldn’t exist.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.